Volume 741 — Federal Reporter, Third Series

<p>Non-Argument Calendar.</p>

<p>Non-Argument Calendar.</p>

United States of America v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014), was a decision in the United States Court of Appeals for the District of Columbia Circuit filed on February 4, 2014 concerning more than minimally manipulated cell therapies and whether they are considered part of medical practice or a drug, the latter subjecting it to regulation under the Food and Drug Administration (FDA). Regenerative Sciences LLC marketed a therapy procedure called Regenexx-C for the treatment of arthritis and orthopedic injury that involved extraction and culture of mesenchymal stem cells from the same patient which were later reinjected.